India Pharma Outlook Team | Thursday, 10 September 2026
Pharma today watches capital, investment, and biosimilars shape new moves that strengthen different layers of India’s drug industry.
Sun Pharma creates a dedicated global treasury unit inside GIFT City to manage international financial operations.
ChrysCapital steps in with a large stake purchase in Linux Laboratories, bringing private equity muscle to a CNS-focused formulations company.
Lupin secures marketing approval for its pegfilgrastim biosimilar and prepares to supply an important oncology-supportive therapy from its Nagpur plant.
These three developments run in parallel and reveal how leading firms organize capital, attract specialized investors and convert complex biologics into market-ready products.
Sun Pharmaceutical Industries incorporates Sun Pharma Global Treasury Centre IFSC Ltd as a wholly-owned indirect subsidiary at the International Financial Services Centre in Gujarat’s GIFT City. The company completed the incorporation on September 8.
Sun Pharma Laboratories holds 100 per cent of the equity, including nominee shareholders. The group injects an initial cash subscription of about Rs 9.50 crore into the share capital. The management will seek registration and approval from the International Financial Services Centers Authority before the unit begins its proposed activities.
This structure places a specialized treasury vehicle inside a jurisdiction built for cross-border financial services. By housing the entity in GIFT City, Sun Pharma gains a platform that can handle global cash management, hedging and funding under a tailored regulatory regime.
The move signals that large Indian drugmakers now treat sophisticated capital organization as a core capability rather than a back-office function.
Also Read: How Can India Pharma Bridge the Gap Between Innovation and Access
ChrysCapital prepares to acquire a 20-25 per cent stake in Linux Laboratories for roughly USD 60-65 million, equivalent to about Rs 600 crore. Tata Capital Healthcare Fund, which currently owns 15.32 per cent, will exit its entire holding.
ChrysCapital will take over that stake and add another 5-10 per cent through a primary capital infusion. Founders Keerthivasan K, Ananda Kumar Sundharam and Hariharan Parameswaran continue to hold the majority with their present 84.68 per cent.
Linux Laboratories, founded in 2007 and headquartered in Chennai, concentrates on central nervous system therapies. Its portfolio spans more than 64 brands and nearly 180 products across neurology, psychiatry and cosmetic dermatology.
Sources project revenue of Rs 450-500 crore and EBITDA of Rs 85-90 crore for FY27. Tata Capital Healthcare Fund had invested Rs 80 crore in the company in 2021. Private equity continues to favor domestic branded-generics businesses that possess established brands and exposure to chronic or specialty therapies.
ChrysCapital already demonstrates this preference through earlier bets: it invested about USD 70 million in La Renon Healthcare at USD 800 million valuation, supported Mankind Pharma, Eris Lifesciences, Torrent Pharmaceuticals and Ipca Laboratories, and recently acquired a controlling 70.68 per cent stake in Novartis India.
Since its inception in 1999, the firm has raised close to USD 8.5 billion across its funds and deployed more than USD 5.5 billion into over 110 portfolio companies. The Linux transaction therefore extends a clear pattern of backing focused domestic players that generate healthy margins.
Lupin Limited obtains marketing approval to manufacture and sell its biosimilar version of pegfilgrastim in India. The company will produce the product at its Nagpur facility in Maharashtra.
Pegfilgrastim helps the body generate neutrophils after chemotherapy and thereby reduces the risk of serious infections and fever caused by chemotherapy-induced neutropenia.
Lupin’s Indian approval therefore adds a new domestic manufacturing source for a therapy that supports cancer patients during chemotherapy. The decision leverages existing plant capacity and builds on the company’s earlier US success with the same molecule.
Sun Pharma’s treasury subsidiary strengthens the financial architecture that Indian drugmakers require. ChrysCapital’s investment supplies growth capital to a specialized CNS formulations company and allows an earlier investor to realize returns.
Lupin’s biosimilar approval converts development work into a tangible product that addresses an important oncology need. Each move rests on concrete steps reported by the companies: incorporation of a new IFSC entity, a structured private-equity stake purchase with a clear exit for the previous investor, and a regulatory clearance for domestic manufacturing and marketing.
Together, they illustrate how capital organization, targeted investment, and biosimilar advancement now operate as parallel engines of growth. Indian pharma continues to build the financial tools, attract specialized capital, and bring complex therapies to patients in a coordinated fashion.
